KR20240082341A - MerTK에 특이적으로 결합하는 항체 또는 이의 단편, 및 항종양제 - Google Patents

MerTK에 특이적으로 결합하는 항체 또는 이의 단편, 및 항종양제 Download PDF

Info

Publication number
KR20240082341A
KR20240082341A KR1020247010037A KR20247010037A KR20240082341A KR 20240082341 A KR20240082341 A KR 20240082341A KR 1020247010037 A KR1020247010037 A KR 1020247010037A KR 20247010037 A KR20247010037 A KR 20247010037A KR 20240082341 A KR20240082341 A KR 20240082341A
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
seq
sequence represented
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247010037A
Other languages
English (en)
Korean (ko)
Inventor
마사요시 토요우라
히로아키 캄바야시
아츠시 사와다
아키 타케스에
토시카즈 이노우에
Original Assignee
치오메 바이오사이언스 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 치오메 바이오사이언스 가부시키가이샤 filed Critical 치오메 바이오사이언스 가부시키가이샤
Publication of KR20240082341A publication Critical patent/KR20240082341A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020247010037A 2021-10-15 2022-09-16 MerTK에 특이적으로 결합하는 항체 또는 이의 단편, 및 항종양제 Pending KR20240082341A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021169289 2021-10-15
JPJP-P-2021-169289 2021-10-15
PCT/JP2022/034801 WO2023063026A1 (ja) 2021-10-15 2022-09-16 ＭｅｒＴＫに特異的に結合する抗体又はその断片、及び抗腫瘍剤

Publications (1)

Publication Number Publication Date
KR20240082341A true KR20240082341A (ko) 2024-06-10

Family

ID=85987671

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247010037A Pending KR20240082341A (ko) 2021-10-15 2022-09-16 MerTK에 특이적으로 결합하는 항체 또는 이의 단편, 및 항종양제

Country Status (9)

Country Link
US (1) US20250326862A1 (https=)
EP (1) EP4417625A4 (https=)
JP (1) JPWO2023063026A1 (https=)
KR (1) KR20240082341A (https=)
CN (1) CN118215684A (https=)
AU (1) AU2022368026A1 (https=)
CA (1) CA3233968A1 (https=)
IL (1) IL311952A (https=)
WO (1) WO2023063026A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020076799A1 (en) 2018-10-09 2020-04-16 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7211703B2 (ja) * 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
BR112021020867A2 (pt) * 2019-04-19 2022-01-04 Genentech Inc Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
JP2023506465A (ja) * 2019-12-13 2023-02-16 アレクトル エルエルシー 抗ＭｅｒＴＫ抗体及びその使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020076799A1 (en) 2018-10-09 2020-04-16 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
https://www.surfaceoncology.com/wp-content/uploads/Surface_AACR19_190307c.pdf
Immunity. 2020 Feb 18; 52(2): 357-373. e9. doi: 10. 1016/j. immuni. 2020. 01. 014. Epub 2020 Feb 11
Pharmacol Ther. 2021 Sep; 225: 107822. doi: 10. 1016/j. pharmthera. 2021. 107822. Epub 2021 Mar 10
Toxicol Pathol. 2018 Feb; 46(2): 193-201. doi: 10. 1177/0192623317749469. Epub 2018 Jan 8

Also Published As

Publication number Publication date
CN118215684A (zh) 2024-06-18
EP4417625A1 (en) 2024-08-21
IL311952A (en) 2024-06-01
EP4417625A4 (en) 2026-01-14
CA3233968A1 (en) 2023-04-20
WO2023063026A1 (ja) 2023-04-20
JPWO2023063026A1 (https=) 2023-04-20
US20250326862A1 (en) 2025-10-23
AU2022368026A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
TWI816729B (zh) 抗tigit抗體及其作為治療和診斷的用途
JP7765397B2 (ja) 新規抗ｌｉｌｒｂ４抗体および派生産物
US11746148B2 (en) Antibody molecules comprising a single-domain antigen-binding site and Fab fragments
TWI718118B (zh) 針對ｒｏｒ１之特異性抗體及嵌合抗原受體
CN112552401B (zh) 抗pd1抗体及其作为治疗剂与诊断剂的用途
JP6998857B2 (ja) Ｃｄ７９に結合する抗体分子
CA3170025A1 (en) Pvrig binding protein and its medical uses
CN116655790A (zh) 抗tim-3抗体及其用途
JP2022514179A (ja) 新規アゴニスト抗ｔｎｆｒ２抗体分子
TW202210521A (zh) 對cd19具專一性之抗體及嵌合抗原受體
CN114981303A (zh) 人源化抗Claudin 18.2（CLDN18.2）抗体
JP7843824B2 (ja) 抗体および使用方法
WO2021097800A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
JP2022512905A (ja) 新規アンタゴニスト抗ｔｎｆｒ２抗体分子
WO2017026331A1 (ja) 抗体
TW202309083A (zh) 抗ｃｌｄｎ４－抗ｃｄ１３７雙特異性抗體
JP2026508244A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びそれを含む多重特異性抗体
CN116635071A (zh) 抗tspan8-抗cd3双特异性抗体和抗tspan8抗体
US20250326840A1 (en) BISPECIFIC ANTIBODY TARGETING SIRP-alpha AND PD-L1 OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE
KR20240082341A (ko) MerTK에 특이적으로 결합하는 항체 또는 이의 단편, 및 항종양제
TW202340250A (zh) 標靶ｃｄ２５的抗體及其製備方法和應用
TW202342528A (zh) 抗人類ｃｘｃｌ１抗體
CN116997354A (zh) 用于诊断和治疗用途的针对lilrb1的单克隆抗体
EA050733B1 (ru) Биспецифическое анти-cldn4/анти-cd137 антитело
HK40031598A (en) Anti-tigit antibodies and their use as therapeutics and diagnostics

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240326

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250526

Comment text: Request for Examination of Application